Navigation Links
Orphan Drug Market to Reach $112 Billion in 2017: Bcc Research

Wellesley, MA (PRWEB) July 16, 2013

In the new report, GLOBAL MARKETS FOR ORPHAN DRUGS (PHM038D), from BCC Research (, the global market for orphan drugs was valued at $82.6 billion in 2011 and nearly $86 billion in 2012. The report forecasts total market value to reach $112 billion in 2017, after increasing at a five-year compound annual growth rate (CAGR) of 5.4%.

Orphan drugs are drugs that treat orphan diseases. An orphan disease is a disease that does not receive significant investment, research, or attention from the medical and pharmaceutical industries. Orphan diseases are most often rare diseases and are defined by using a ratio of incidence to population in the U.S., the EU, Japan and other developed countries. An orphan disease can also be a tropical disease whose typical sufferers cannot afford access to pharmaceutical treatment options.

Orphan diseases did not receive much attention from the pharmaceutical industry until the U.S. passed the first Orphan Drug Act in 1983. Other countries quickly began following suit with versions of the Orphan Drug Act. Before governments began passing these acts, the pharmaceutical industry could not make a profit from orphan drugs because of the small market size. Government intervention opened a path to profitability for pharmaceutical companies and created an interest to develop orphan drugs.

BCC Research’s Report analyzes the market for orphan drugs by region, by biological and non-biological drug type, by active ingredient, and by area of medical application. The report reveals why orphan drugs for oncology are the largest category for both biological and non-biological drugs. The report includes a detailed analysis of all other categories within biological and non-biological drugs.

This BCC Research report also provides a detailed explanation of the current market value, forecast, and growth rate for the next five years for both the biological and non-biological orphan drug segments. BCC Research valued the biological orphan drug segment at $57.7 billion in 2012, and expects the value to reach nearly $71.4 billion in 2017, registering a CAGR (compound annual growth rate) of 4.3%. The report valued non-biological orphan drugs at $28.3 billion in 2012, and forecasts the market to reach $40.8 billion in 2017, after growing at a CAGR (compound annual growth rate) of 7.5%.

Some of the growth drivers for the orphan drugs market discussed by BCC Research in the report include increased research and development, new technology, additional regulatory easing, and new product launches. Additionally, the ability of pharmaceutical companies to use orphan drugs for off-label uses is also helping in achieving market growth.

This BCC Research report provides insights into the regulations and laws that are allowing the orphan drugs market to grow. BCC Research’s report provides clear and precise guidance on every aspect of the industry.

The study will be beneficial to pharmaceutical and biotechnical companies, research institutes, and physicians.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Ground Broken For New Orphanage In Africa Thanks To Living Fuel And FreeRide836 Kiteboarders
2. Tellurex Sends tPOD1™ to Light Up Orphanage in Uganda
3. FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa
4. 30 Years of Orphan Drug Act, Combined with Science and Advocacy, Reflect Dramatic Progress in a Rare Lung Disease, Pulmonary Hypertension Association Says
5. First Pathfinder Awards announced tackling rare and orphan diseases
6. Clinical Next Generation Sequencing Market: NGS Diagnostic 2018 Forecast in New Industry Research Report at
7. Breast Pumps Market Is Expected to Reach USD 1.03 Billion Globally in 2018 : Transparency Market Research
8. Modular Data Center Market Is Expected to Reach $40.41 Billion by 2018 at a CAGR of 37.41% From 2013 to 2018 - New Report by MarketsandMarkets
9. SevenPoint2, the Alkaline Company, Is Finding a Marketing ‘Balance’ with CallFire’s Tele-pH-ony Solutions
10. Marshall Fong Joins FMC BioPolymer as Global Marketing Director of Food Ingredients
11. Pre-Harvest Market to Reach $55,696.6 Million by 2018 at a CAGR of 5.7% - New Report by MarketsandMarkets
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... at the Radiology Society of North America (RSNA) annual meeting, being held November ... growth from 2014. Throughout 2015, the company has completed installations for Integrated ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – ... leading plastic surgery practices in Florida, is proud to announce that Dr. Joshua ... innovations giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra ... TIGR® Matrix Surgical Mesh technology for soft tissue repair in the US via ... a long-term resorbable surgical mesh intended to support and reinforce soft tissue for ...
(Date:11/30/2015)... ... ... TransPack Volume 6 features 30 customizable transitions created exclusively for use within ... with blur & drop shadow options. Utilize the controls in the inspector window ... the next with TransPack's easily customizable styles. , TransPack Volume 6 features ...
(Date:11/30/2015)... ... November 30, 2015 , ... Workstation ... more than 30 HealthPostures’ dealers located throughout the United States, is OneStop Ergonomics. ... of corporate, industrial, manufacturing and government workers and organizational leaders that are introduced ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
(Date:11/30/2015)... BOSTON , November 30, 2015 ... medicines directed at up to 10 G protein-coupled receptor ... PFE ) to research and develop potential new medicines ... targets across multiple therapeutic areas. --> Heptares ... development company and wholly-owned subsidiary of Sosei Group Corporation ...
(Date:11/30/2015)... TEL AVIV, Israel , November 30, 2015 /PRNewswire/ ... EMITF ) ("Elbit" or the "Company") announced today that it ... Ministry of Food and Drug Safety (MFDS) has approved ... behavioral disorders. --> --> ... presenting a non-invasive treatment alternative that combines two technologies: ...
Breaking Medicine Technology: